Method for preparing adjuvant
By using liposome compositions of phosphatidylcholine and cholesterol, combined with solvent injection method and microjet homogenization technology, the problem of size and polydispersity control of liposome adjuvant preparations is solved, and a suitable for large-scale production is achieved Stable and consistent formulations.
Patent Information
- Application Number
- CN202380027604.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-20
- Filing Date
- 2023-03-09
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to control the size and polydispersity of liposome adjuvant preparations containing MPLA and saponins, and it is difficult to expand production on a large scale, resulting in problems of drug packaging differences and stability.
The size and polydispersity of the liposomes are controlled by solvent injection method and microjet homogenization technology to form a size and polydispersity with a size range of about 30-400 nm and 0.05-0.5. Polydispersible adjuvant preparation.
Repeatable control of the size and polydispersity of MPLA and saponin liposome adjuvant preparations is achieved, suitable for large-scale production, improve the stability and consistency of the preparations, and is suitable for clinical and commercial manufacturing.
Smart Images

Figure CN118900684A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 485,964, filed on February 20, 2023, and U.S. Provisional Application No. 63 / 319,418, filed on March 14, 2022. The entire contents of each of the above applications are incorporated herein by reference. Technical Field
[0003] The present invention provides a method for preparing homogeneous and heterogeneous adjuvant formulations comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG) and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), and the present invention further provides an adjuvant formulation produced by the method. Background of the Invention
[0005] In 2017, the United States used a commercial liposome adjuvant formulation (called AS01) containing both monophosphoryl lipid A (MPLA) and QS-21 saponin for adults aged >50 years as an adjuvant for the shingles vaccine. The U.S. Army has developed another liposome-based formulation containing both MPLA and QS-21 saponin, which is called Army Liposome Formulation Q (ALFQ). ALFQ has been shown to be effective as a liposome vaccine adjuvant in rodent and non-human primate studies, and it has also been shown to be non-pyrogenic and non-toxic in preclinical studies. The improved safety properties of ALFQ can be attributed to the irreversible binding of liposomal cholesterol to free QS-21 to form a complex that prevents hemolysis of red blood cells caused by the binding of QS-21 to them. When soluble QS-21 is added to the suspension of the liposome intermediate, the size of ALFQ increases from 50 to 100 nm to about 30,000 nm during the manufacture of ALFQ. As described in the literature, ALFQ liposome intermediates are prepared by a rehydration method (Beck et al., Biochimica et Biophysica Acta 1848 (2015) 775-780; Singh et al., Biochemical and Biophysical Research Communications 529 (2020) 362-365; Matyas et al., Methods in Enzymology 373 (2003) 34-50). In this method, lipids are mixed and dissolved in an organic solvent, dried in a vacuum, and then liposomes are formed in PBS and reduced in size to 30 to 100 nm by a microfluidizer. The most widely used of these methods is to deposit a thin lipid film (from an organic solvent) on the wall of a container, add an aqueous solution of the material to be encapsulated, and stir the container (Bangham et al., J. Mol. Biol. 13 (1965) 238-252). Under appropriate conditions, this method leads to the formation of multilamellar vesicles of liposomes. However, this method is usually not scalable due to the size limitations of the equipment used (ie, a rotary evaporator; Rotavap).
[0006] In another method, an organic solution of lipids is freeze-dried to produce a freeze-dried product with physical properties that are easily hydrated by an aqueous solution of the material to be encapsulated. Problems associated with this production method include the variability of drug encapsulation in liposomes between batches. For example, Conrad et al. (Biochim. Biophys. Acta 332 (1974) 36-46) showed that the standard deviation of encapsulation efficiency was 12% to 13% between liposome preparations prepared independently using this method.
[0007] Therefore, there is a need for a reproducible method to control the size and polydispersity of liposomal adjuvant formulations containing MPLA and saponins (including but not limited to QS-21). In addition, there is a need for a method that is sufficiently stable for large-scale use (i.e., scalable to clinical and commercial manufacturing).
[0008] Brief description of the invention
[0009] The present invention provides a novel and reproducible method for controlling the size and polydispersity of liposome adjuvant formulations comprising MPLA and saponins (including but not limited to QS-21). In addition, the present invention provides a method for large-scale manufacturing of said liposome adjuvant formulations comprising MPLA and saponins, wherein large-scale manufacturing (i.e., scalable manufacturing) produces liposome adjuvant formulations in quantities sufficient for clinical and commercial use.
[0010] The present invention provides a first method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG) and distearoylphosphatidylglycerol (DSPG) and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0011] The method comprises the following steps:
[0012] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form an organic phase;
[0013] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0014] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0015] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0016] (v) concentrating the intermediate liposomes in step (iv); and
[0017] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0018] The homogenous adjuvant formulation is thereby produced.
[0019] In one embodiment of the first method for producing a homogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred embodiment, the saponin is QS-21.
[0020] The present invention provides a second method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0021] The method comprises the following steps:
[0022] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent or a mixture of organic solvents to form an organic phase;
[0023] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form intermediate liposomes;
[0024] (iii) concentrating the intermediate liposomes in step (ii);
[0025] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0026] (v) filtering the intermediate liposomes in step (iv); and
[0027] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0028] The homogenous adjuvant formulation is thereby produced.
[0029] In one embodiment of the second method for producing a homogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred embodiment, the saponin is QS-21.
[0030] The present invention provides a first method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0031] The method comprises the following steps:
[0032] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid solution as an organic phase;
[0033] (ii) injecting the organic phase in step (i) together with the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase simultaneously to form liposomes;
[0034] (iii) concentrating the intermediate liposomes in step (ii);
[0035] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0036] (v) processing the intermediate liposomes from step (iv) through a microfluidizer at about 17,500 psi for 10 times;
[0037] (vi) filtering the intermediate liposomes in step (v) using a 0.22 μm membrane; and
[0038] (vii) mixing the intermediate liposomes in step (vi) with saponin,
[0039] The heterogeneous adjuvant formulation is thereby produced.
[0040] In one embodiment of the first method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0041] The present invention provides a second method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0042] The method comprises the following steps:
[0043] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid preparation as an organic phase;
[0044] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0045] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0046] (iv) concentrating the intermediate liposomes in step (iii);
[0047] (v) removing the organic phase of the intermediate liposomes in step (iv); and
[0048] (vi) mixing the intermediate liposomes in step (v) with saponin,
[0049] The heterogeneous adjuvant formulation is thereby produced.
[0050] In one embodiment of the second method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0051] The present invention provides a third method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0052] The method comprises the following steps:
[0053] (i) preparing a lyophilized organic phase comprising phospholipids, cholesterol and MPLA;
[0054] (ii) rehydrating the lyophilized organic phase in step (i) with an aqueous phase to form intermediate liposomes;
[0055] (iii) reducing the size of the intermediate liposomes in step (ii) using a microfluidizer;
[0056] (iv) mixing the intermediate liposomes in step (iii) with saponin,
[0057] The heterogeneous adjuvant formulation is thereby produced.
[0058] In one embodiment of the third method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0059] The invention also provides an adjuvant formulation produced by any of the methods described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 Shown are the neutralization titers of individual animals (rats) immunized with C. difficile toxoid antigen formulated with different LiNA-2 adjuvants (homogeneous and heterogeneous). DETAILED DESCRIPTION OF THE INVENTION
[0063] The present invention relates to a method for preparing an adjuvant formulation comprising a liposome composition containing monophosphoryl lipid A (MPLA) and at least one saponin (e.g., QS-21). Examples of such non-toxic adjuvant formulations are described in U.S. Pat. No. 10,434,167 and PCT International Publication No. WO2015148648, each of which is incorporated herein by reference in its entirety. The adjuvant formulation comprises a liposome composition containing monophosphoryl lipid A (MPLA) and at least one saponin, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids and ii) cholesterol at a molar percentage concentration greater than about 50% (mol / mol) of the liposome composition. The saponin may be selected from QS-7, QS-18, QS-21, or a mixture thereof. Preferably, the saponin is QS-21.
[0064] Thus, the adjuvant formulation comprises a liposome composition comprising monophosphoryl lipid A (MPLA) and at least one saponin, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids and ii) cholesterol, wherein the molar ratio of cholesterol to phospholipids is greater than about 1. The saponin may be selected from QS-7, QS-18, QS-21 or a mixture thereof. Preferably, the saponin is QS-21. Various methods are described herein to prepare heterogeneous and homogeneous liposomal adjuvant formulations that can be scaled up for manufacturing. The homogeneous method is a controllable and stable method that produces liposomes of controlled size. Both adjuvant formulations comprise liposomes containing MPLA, and the MPLA-containing liposomes comprise a saponin (e.g., QS-21). The non-toxic adjuvant formulation described in U.S. Pat. No. 10,434,167 is a highly heterogeneous product that is manufactured by a method that is extremely difficult to scale up for clinical or commercial manufacturing. Example 3 describes three new methods for manufacturing this heterogeneous liposomal adjuvant formulation. These new methods are highly reproducible and can be easily scaled up for clinical and commercial manufacturing.
[0065] Examples 1 and 2 describe two methods that can be scaled up for the manufacture of homogeneous liposome adjuvant formulations containing the same components as the heterogeneous liposome adjuvant formulations described in U.S. Pat. No. 10,434,167. Homogeneous formulations having liposomes in a size range of less than 1 micron and a controllable polydispersity index (PDI) ranging from 0.05 to 0.3 were manufactured by the methods described in Examples 1 and 2. The methods described herein are reproducible and well controlled, and are capable of manufacturing homogeneous liposome adjuvant formulations of defined sizes.
[0066] Also described herein are a variety of novel solvent injection methods for preparing intermediate liposomes. Solvent injection involves rapidly injecting a lipid solution in ethanol or other organic solvents into an aqueous medium. The method is performed at room temperature or at a higher temperature (e.g., 60° C.). The size of the intermediate liposomes produced is 30 nm to 200 nm, with PDI <0.25. The size and PDI of the intermediate can be controlled by adjusting the parameters of solvent injection (such as temperature, flow rate, flow rate ratio of organic phase to aqueous phase) or by treatment with a microfluidizer. The final size of the liposome adjuvant formulation can be affected by the size and manufacturing method of the intermediate liposomes described herein (e.g., the number of times treated with a microfluidizer, etc.).
[0067] In addition, the article also describes the preparation of heterogeneous liposomes using freeze-dried lipids. In this preparation, there is no problem of drug loading variation among different batches because there is no drug in the adjuvant formulation. This method ensures consistency between batches and helps quality control at clinical and commercial scales.
[0068] In general, novel methods for preparing adjuvant formulations are provided herein, comprising MPLA-containing liposome compositions comprising saponins (e.g., QS-21). Compared with conventional methods, these methods can control the size and polydispersity of liposome adjuvant formulations and can be easily scaled up for clinical and commercial manufacturing with reproducibility. In addition, a novel MPLA-containing homogeneous liposome composition is provided herein, comprising saponins (e.g., QS-21).
[0069] Therefore, the present invention provides a first method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG) and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0070] The method comprises the following steps:
[0071] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form an organic phase;
[0072] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0073] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0074] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0075] (v) concentrating the intermediate liposomes in step (iv); and
[0076] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0077] Thereby the homogeneous adjuvant formulation is produced.
[0078] In one embodiment of the first method for producing a homogeneous adjuvant composition, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred embodiment, the saponin is QS-21.
[0079] In another embodiment of the first method for producing a homogeneous adjuvant composition, wherein in step (i), the phospholipids, cholesterol and MPLA are dissolved in an organic solvent by sonication, heating or a combination thereof (preferably by heating). In one aspect, the organic solvent is ethanol or isopropanol. In another aspect, the organic phase is heated to a temperature between 45° C. and 65° C.
[0080] In another embodiment of the first method for producing a homogeneous adjuvant composition, the aqueous phase comprises water and an optional buffer. In a preferred aspect, the buffer comprises 10mM phosphate containing 150mM NaCl at pH 6.2. In a preferred aspect, the aqueous phase is a 10mM phosphate solution containing 150mM NaCl at pH 6.2. In another aspect, the aqueous phase is at a temperature between 20°C and 60°C. In another aspect, the flow rate in step (ii) is 0.5mL / min to 400mL / min or is added quickly. In another aspect, the flow rate in step (ii) is 0.5mL / min to 400mL / min. In another aspect, the injection in step (ii) is carried out by rapidly injecting the organic phase in step (i).
[0081] In another embodiment of the first method for producing a homogenous adjuvant composition, the intermediate liposomes in step (iii) are stirred at a rate of 700 rpm to 900 rpm.
[0082] In another embodiment of the first method for producing a homogeneous adjuvant composition, the ratio of the organic phase to the aqueous phase of step (ii) is in the range of 1:4 to 1: 16. In a preferred embodiment, the ratio is 1:8.
[0083] In another embodiment of the first method for producing a homogenous adjuvant composition, the size of the intermediate liposomes in step (iv) is reduced by using a high pressure extruder or a microfluidizer. In one aspect, the size of the liposomes is reduced in step (iv) by using a membrane size in the range of 50 nm to 120 nm or a homogenization pressure between 17000 PSI and 24000 PSI, or a combination of the two.
[0084] In another embodiment of the first method for producing a homogeneous adjuvant composition, the organic solvent is removed before the size reduction in step (iv) or after the size reduction in step (iv). In one aspect, the organic phase of the intermediate liposomes in step (iv) is removed by tangential flow filtration (TFF). In another aspect, the TFF is TFF diafiltration. In another aspect, the TFF comprises a membrane with a molecular weight cutoff (MWCO) in the range of 100 kDa to 500 kDa.
[0085] In another embodiment of the first method for producing a homogenous adjuvant composition, the concentration in step (v) is performed by ultrafiltration. In one aspect, the ultrafiltration comprises a bioburden reduction filter and a sterile filter.
[0086] In another embodiment of the first method for producing a homogeneous adjuvant composition, the mixing in step (vi) is performed at a mixing speed of 300 rpm. In one aspect, the mixing in step (vi) is in the range of 1 hour to 24 hours. In another aspect, the mixing in step (vi) is performed at room temperature or at 2 to 8°C.
[0087] In another embodiment of the first method for producing a homogeneous adjuvant composition, the final adjuvant preparation has a size range of about 30 nm to 400 nm.
[0088] In another embodiment of the first method for producing a homogeneous adjuvant composition, the final adjuvant formulation has a polydispersity of 0.05 to 0.5.
[0089] In another embodiment of the first method for producing a homogeneous adjuvant composition, the injecting in step (ii) is performed by pump or syringe injection. In a preferred aspect, the injecting in step (ii) is performed by a pump.
[0090] In one embodiment of the first method for producing a homogeneous adjuvant composition, the at least one phospholipid is a mixture of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
[0091] In one embodiment, the first method for producing a homogeneous adjuvant formulation comprises a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition comprising (i) at least one phospholipid, wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid in the liposome composition is greater than 1,
[0092] The method comprises the following steps:
[0093] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form an organic phase;
[0094] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0095] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0096] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0097] (v) concentrating the intermediate liposomes in step (iv); and
[0098] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0099] Thereby the homogeneous adjuvant formulation is produced.
[0100] The present invention provides a second method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0101] The method comprises the following steps:
[0102] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent or a mixture of organic solvents to form an organic phase;
[0103] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form intermediate liposomes;
[0104] (iii) concentrating the intermediate liposomes in step (ii);
[0105] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0106] (v) filtering the intermediate liposomes in step (iv); and
[0107] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0108] Thereby the homogeneous adjuvant formulation is produced.
[0109] In one embodiment of the second method for producing a homogeneous adjuvant composition, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred embodiment, the saponin is QS-21.
[0110] In another embodiment of the second method for producing a homogeneous adjuvant composition, the phospholipids, cholesterol and MPLA in step (i) are dissolved in an organic solvent by ultrasonic treatment, heating, stirring or a combination thereof. In one aspect, the organic solvent is ethanol or isopropanol or other organic solvents. In one aspect, the organic solvent is ethanol or isopropanol. In another aspect, the organic phase is heated to a temperature between 45°C and 65°C, preferably, between 50°C and 65°C or between 45°C and 55°C.
[0111] In another embodiment of the second method for producing a homogeneous adjuvant composition, the aqueous phase comprises water and an optional buffer. In one aspect, the buffer comprises 10mM phosphate containing 150mM NaCl at about pH 6.2. In a preferred aspect, the aqueous phase is a 10mM phosphate solution containing 150mM NaCl at pH 6.2. In another aspect, the aqueous phase is at a temperature between 20°C and 65°C. In another aspect, the flow rate in step (ii) is 5mL / min to 15mL / min. In another aspect, the flow rate in step (ii) is 12mL / min. In another aspect, the intermediate liposome in step (ii) is stirred at a rate of 100rpm to 1000rpm. In another aspect, the ratio of the organic phase to the aqueous phase in step (ii) is between 1:2 and 1:16. In a preferred embodiment, the ratio is 4:7.
[0112] In another embodiment of the second method for producing a homogeneous adjuvant composition, the concentration in step (iii) is performed by ultrafiltration.
[0113] In another embodiment of the second method for producing a homogeneous adjuvant composition, the organic phase of the intermediate liposomes in step (iv) is removed by tangential flow filtration (TFF). In one aspect, the TFF is a TFF diafiltration. In another aspect, the TFF comprises a membrane with a molecular weight cut-off (MWCO) in the range of 100 kDa to 500 kDa.
[0114] In another embodiment of the second method for producing a homogenous adjuvant composition, the filtration in step (v) comprises a bioburden reduction filter and a sterile filter.
[0115] In another embodiment of the second method for producing a homogeneous adjuvant composition, the mixing in step (vi) is performed at a mixing speed of 350 rpm for 1 hour at room temperature.
[0116] In another embodiment of the second method for producing a homogenous adjuvant composition, the final adjuvant preparation has a size range of about 50 nm to 200 nm. Preferably, the final adjuvant preparation has a size of about 100 nm.
[0117] In another embodiment of the second method for producing a homogeneous adjuvant composition, the final adjuvant formulation has a polydispersity of 0.05 to 0.5. Preferably, the final adjuvant formulation has a PDI of < 0.2.
[0118] In another embodiment of the second method for producing a homogeneous adjuvant composition, the injecting in step (ii) is performed by pump or syringe injection. In a preferred aspect, the injecting in step (ii) is performed by a pump.
[0119] In one embodiment of the second method for producing a homogenous adjuvant composition, the at least one phospholipid is a mixture of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
[0120] In one embodiment, the second method for producing a homogeneous adjuvant formulation comprises a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid is greater than 1,
[0121] The method comprises the following steps:
[0122] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent or a mixture of organic solvents to form an organic phase;
[0123] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form intermediate liposomes;
[0124] (iii) concentrating the intermediate liposomes in step (ii);
[0125] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0126] (v) filtering the intermediate liposomes in step (iv); and
[0127] (vi) mixing the intermediate liposomes from step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5,
[0128] Thereby the homogeneous adjuvant formulation is produced.
[0129] The present invention provides a first method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0130] The method comprises the following steps:
[0131] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid solution as an organic phase;
[0132] (ii) injecting the organic phase in step (i) together with the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase simultaneously to form liposomes;
[0133] (iii) concentrating the intermediate liposomes in step (ii);
[0134] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0135] (v) processing the intermediate liposomes from step (iv) through a microfluidizer at about 17,500 psi for 10 times;
[0136] (vi) filtering the intermediate liposomes in step (v) using a 0.22 μm membrane; and
[0137] (vii) mixing the intermediate liposomes in step (vi) with saponin,
[0138] Thereby the heterogeneous adjuvant formulation is produced.
[0139] In one embodiment of the first method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0140] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, in step (i), phospholipids, cholesterol and MPLA are dissolved in an organic solvent by ultrasonic treatment, heating, stirring or a combination thereof. In one aspect, the organic solvent is ethanol or isopropanol or a mixture thereof. In another aspect, the lipid formulation organic phase is heated to a temperature of 45° C. to 65° C.
[0141] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the aqueous phase comprises water and an optional buffer. In one aspect, the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.2. In a preferred aspect, the aqueous phase is a 10 mM phosphate solution containing 150 mM NaCl at pH 6.2. In another aspect, the aqueous phase is at a temperature between 45°C and 60°C.
[0142] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, in step (ii), the organic phase has a flow rate of 0.5 to 2 ml / min and the aqueous phase has a flow rate of 5 to 15 ml / min. In another embodiment of the third method, in step (ii), the organic phase has a flow rate of 1.333 ml / min and the aqueous phase has a flow rate of 10.667 ml / min.
[0143] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the intermediate liposomes in step (iii) are stirred at a rate of 100 rpm to 900 rpm.
[0144] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the ratio of the organic phase to the aqueous phase in step (ii) is in the range of 1:4 to 1:8. In a preferred aspect, the ratio is 1:8.
[0145] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the organic phase of the intermediate liposomes in step (iii) and step (iv) is removed by tangential flow filtration (TFF). In one aspect, the TFF is TFF ultrafiltration and diafiltration. In another aspect, the TFF comprises a membrane with a molecular weight cutoff (MWCO) in the range of 100 kDa to 500 kDa.
[0146] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the concentration in step (iii) is performed by ultrafiltration.
[0147] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the size of the intermediate liposomes in step (iv) is manipulated by using a microfluidizer.
[0148] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the organic solvent is removed prior to the microfluidization in step (v).
[0149] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, a buffer is added to the mixing in step (vii). In one aspect, the mixing in step (vii) is carried out at room temperature at a mixing speed of 350 rpm for 1 hour to 48 hours or stirring for 1 hour. In another aspect, after the mixing in step (vii), the intermediate liposomes are stored at room temperature for up to 48 hours without stirring.
[0150] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a size of about 300 nm to 1000 nm.
[0151] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a polydispersity of 0.4 to 1.0.
[0152] In another embodiment of the first method for producing a heterogeneous adjuvant formulation, the injecting in step (ii) is performed by Nanoassemblyr or pump or syringe injection.
[0153] In one embodiment of the first method for producing a heterogeneous adjuvant formulation, the at least one phospholipid is a mixture of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
[0154] In one embodiment, the first method for producing a heterogeneous adjuvant formulation comprises a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid is greater than 1,
[0155] The method comprises the following steps:
[0156] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid solution as an organic phase;
[0157] (ii) injecting the organic phase in step (i) together with the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase simultaneously to form liposomes;
[0158] (iii) concentrating the intermediate liposomes in step (ii);
[0159] (iv) removing the organic phase of the intermediate liposomes in step (iii);
[0160] (v) processing the intermediate liposomes from step (iv) through a microfluidizer at about 17,500 psi for 10 times;
[0161] (vi) filtering the intermediate liposomes in step (v) using a 0.22 μm membrane; and
[0162] (vii) mixing the intermediate liposomes in step (vi) with saponin,
[0163] Thereby the heterogeneous adjuvant formulation is produced.
[0164] The present invention provides a second method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, wherein the liposome bilayer comprises (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0165] The method comprises the following steps:
[0166] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid preparation as an organic phase;
[0167] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0168] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0169] (iv) concentrating the intermediate liposomes in step (iii);
[0170] (v) removing the organic phase of the intermediate liposomes in step (iv); and
[0171] (vi) mixing the intermediate liposomes in step (v) with saponin,
[0172] Thereby the heterogeneous adjuvant formulation is produced.
[0173] In one embodiment of the second method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0174] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, in step (i), phospholipids, cholesterol and MPLA are dissolved in an organic solvent by ultrasonic treatment, heating, stirring or a combination thereof. In one aspect, the organic solvent comprises ethyl acetate and isopropanol. In another aspect, the lipid formulation organic phase is heated to a temperature of 50° C. to 65° C.
[0175] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the aqueous phase comprises water and optionally a buffer. In one aspect, the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.2. In a preferred aspect, the aqueous phase is a 10 mM phosphate solution containing 150 mM NaCl at pH 6.2. In another aspect, the aqueous phase is at a temperature of 20° C. to 25° C. In another aspect, the flow rate in step (ii) is 10 to 30 mL / min. In another aspect, the flow rate in step (ii) is 20 mL / min.
[0176] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the intermediate liposomes in step (iii) are stirred at a rate of 100 rpm to 900 rpm.
[0177] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the ratio of the organic phase to the aqueous phase in step (ii) is in the range of 1:4 to 1:8. In a preferred aspect, the ratio is 1:8.
[0178] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the organic solvent is removed prior to mixing in step (vi).
[0179] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the organic phase of the intermediate liposomes in step (iv) and step (v) is removed by tangential flow filtration (TFF). In one aspect, the TFF is TFF ultrafiltration and diafiltration. In another aspect, the TFF comprises a membrane with a molecular weight cutoff (MWCO) in the range of 100 kDa to 500 kDa.
[0180] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the concentration in step (vi) is performed by ultrafiltration.
[0181] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, a buffer is added to the mixing in step (vi).
[0182] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the mixing in step (vi) is performed at a mixing speed of 300 rpm at room temperature for 1 hour. In one aspect, after the mixing in step (vii), the intermediate liposomes are stored at room temperature for 24 hours without stirring.
[0183] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a size range of about 300 nm to 1000 nm.
[0184] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a polydispersity of 0.4 to 1.0.
[0185] In another embodiment of the second method for producing a heterogeneous adjuvant formulation, the injecting in step (ii) is performed by pipette, pump or syringe injection.
[0186] In one embodiment of the second method for producing a heterogeneous adjuvant formulation, the at least one phospholipid is a mixture of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
[0187] In one embodiment, the second method for producing a heterogeneous adjuvant formulation comprises a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid is greater than 1,
[0188] The method comprises the following steps:
[0189] (i) dissolving phospholipids, cholesterol and MPLA in an organic solvent to form a lipid preparation as an organic phase;
[0190] (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes;
[0191] (iii) stirring the liposomes in step (ii) to form intermediate liposomes;
[0192] (iv) concentrating the intermediate liposomes in step (iii);
[0193] (v) removing the organic phase of the intermediate liposomes in step (iv); and
[0194] (vi) mixing the intermediate liposomes in step (v) with saponin,
[0195] Thereby the heterogeneous adjuvant formulation is produced.
[0196] The present invention provides a third method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, wherein the liposome composition comprises (i) at least one phospholipid selected from at least one phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol),
[0197] The method comprises the following steps:
[0198] (i) preparing a lyophilized organic phase comprising phospholipids, cholesterol and MPLA;
[0199] (ii) rehydrating the lyophilized organic phase in step (i) with an aqueous phase to form intermediate liposomes;
[0200] (iii) reducing the size of the intermediate liposomes in step (ii) using a microfluidizer;
[0201] (iv) mixing the intermediate liposomes in step (iii) with saponin,
[0202] Thereby the heterogeneous adjuvant formulation is produced.
[0203] In one embodiment of the third method for producing a heterogeneous adjuvant formulation, the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof. In a preferred aspect, the saponin is QS-21.
[0204] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, in step (i), phospholipids, cholesterol and MPLA are dissolved in an organic solvent by sonication, heating, stirring or a combination thereof. In one aspect, the organic solvent comprises tert-butyl alcohol (TBA) or a mixture thereof. In another aspect, the lipid organic phase is heated to a temperature of 25° C. to 65° C. In another aspect, the organic phase solution is lyophilized.
[0205] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the aqueous phase comprises water or a buffer. In one aspect, the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.2. In a preferred aspect, the aqueous phase is a 10 mM phosphate solution containing 150 mM NaCl at pH 6.2. In another aspect, the aqueous phase is at a temperature of 20° C. to 70° C.
[0206] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the intermediate liposomes in step (ii) are stirred at a rate of 100 to 1000 rpm.
[0207] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the size of the intermediate liposomes in step (iii) is reduced using a microfluidizer and a pressure at or about 18640 PSI.
[0208] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the organic solvent is removed prior to rehydration in step (ii). In one aspect, the organic solvent is removed by lyophilization.
[0209] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, a buffer is added to the mixing in step (iv).
[0210] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the mixing in step (iv) is performed at a mixing speed of 300 rpm or stirring at room temperature for 1 hour.
[0211] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the mixed intermediate liposomes in step (iv) are stored at room temperature for 24 hours without stirring.
[0212] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a size > 300 nm.
[0213] In another embodiment of the third method for producing a heterogeneous adjuvant formulation, the final adjuvant formulation has a polydispersity > 0.4.
[0214] In one embodiment of the third method for producing a heterogeneous adjuvant formulation, the at least one phospholipid is a mixture of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG).
[0215] In one embodiment, the third method for producing a heterogeneous adjuvant formulation comprises a liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition comprising (i) at least one phospholipid selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid is greater than 1,
[0216] The method comprises the following steps:
[0217] (i) preparing a lyophilized organic phase comprising phospholipids, cholesterol and MPLA;
[0218] (ii) rehydrating the lyophilized organic phase in step (i) with an aqueous phase to form intermediate liposomes;
[0219] (iii) reducing the size of the intermediate liposomes in step (ii) using a microfluidizer;
[0220] (iv) mixing the intermediate liposomes in step (iii) with saponin,
[0221] Thereby the heterogeneous adjuvant formulation is produced.
[0222] The invention also provides an adjuvant formulation produced by any of the methods described herein.
[0223] In one aspect, the liposome composition of the adjuvant formulation may comprise cholesterol at a molar percentage concentration of more than 50% (mol / mol), about 55% to about 71% (mol / mol), or preferably about 55% (mol / mol). In one aspect, the liposome composition of the adjuvant formulation may comprise a phosphatidylcholine phospholipid (PC) selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC). In another aspect, the liposome composition of the adjuvant formulation may comprise a phosphatidylglycerol phospholipid (PG) selected from the group consisting of dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), and distearoylphosphatidylglycerol (DSPG). In another aspect, the liposome composition of the adjuvant formulation may comprise (i) a phosphatidylcholine phospholipid (PC) selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC) and distearoylphosphatidylcholine (DSPC), and (ii) a phosphatidylglycerol phospholipid (PG) selected from the group consisting of dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG) and distearoylphosphatidylglycerol (DSPG). The liposome composition of the adjuvant formulation may have a ratio (mol / mol) of PC to PG of about 0.5:1, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1 or about 15:1. The liposome composition of the adjuvant formulation may comprise multilamellar vesicles (MLVs) or small unilamellar vesicles (SUVs), wherein the diameter of the small unilamellar vesicles is about 50 to about 100 nm, and wherein the diameter of the multilamellar vesicles is about 1 to about 4 μm. In a preferred embodiment, the liposome composition of the adjuvant formulation comprises PC and PG, wherein PC is dimyristoylphosphatidylcholine (DMPC) and PG is dimyristoylphosphatidylglycerol (DMPG), and has a molar ratio (mol / mol) of PC to PG of about 9:1.
[0224] In another aspect, the liposome composition of the adjuvant formulation may contain about 5 mg or less, about 4 mg or less, about 3 mg or less, about 2 mg or less, about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less or about 0.01 mg or less of MPLA (based on the total weight in each ml of liposome suspension). The liposome composition of the adjuvant formulation may have a molar ratio of MPLA:phospholipid of about 1:5.6 to about 1:880, or about 1:88 to about 1:220. In a preferred embodiment, the liposome composition of the adjuvant formulation comprises PC and PG, wherein PC is dimyristoylphosphatidylcholine (DMPC) and PG is dimyristoylphosphatidylglycerol (DMPG), and has a molar ratio of MPLA:phospholipid of about 1:220, about 1:88 or about 1:5.6, preferably 1:88.
[0225] In another aspect, the adjuvant formulation can have a saponin content of about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less or about 0.01 mg or less (by gross weight per ml liposome suspension). In a preferred aspect, the adjuvant formulation comprises a saponin content of about 0.2 to 0.4 mg / ml.
[0226] An immunogenic composition comprising an immunogen and an adjuvant preparation is also provided. The immunogenic composition may generally comprise a physiologically acceptable carrier. The immunogen of the immunogenic composition may be selected from the group consisting of: naturally occurring or artificially produced proteins, recombinant proteins, glycoproteins, peptides, carbohydrates, haptens, whole viruses, bacteria, protozoa, and virus-like particles. A method for animal immunization is also provided, comprising administering the immunogenic composition.
[0227] In addition, a method for reducing the toxicity of saponin as an adjuvant or a method for preparing an adjuvant formulation is provided, which comprises adding a liposome composition containing monophosphoryl lipid A (MPLA) to saponin, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids, wherein the melting temperature of the hydrocarbon chain in water is ≥ 23°C, and ii) cholesterol at a molar percentage concentration greater than about 50% (mol / mol). The saponin can be selected from the group consisting of QS-7, QS-18, QS-21 and mixtures thereof. Preferably, the saponin is QS-21. The liposome composition may comprise cholesterol at a molar percentage concentration of about 55% to about 71% (mol / mol), preferably about 55% (mol / mol).
[0228] 1. Definition
[0229] An "immunogen" is a substance capable of inducing a humoral and / or cell-mediated immune response. An immunogen as described herein may be an antigen, a hapten, or an inactivated pathogen. An immunogenic composition as described herein may be, for example, a vaccine formulation.
[0230] As used herein, the term "homogeneous" shall refer to a final adjuvant formulation comprising liposomes having a size range of about 30 nm to 400 nm as determined by methods known in the art, including but not limited to dynamic light scattering (DLS), transmission electron cryomicroscopy (e.g., cryoTEM or cryoEM), nanoparticle tracking analysis (NTA, e.g., ViewSizer). A "homogeneous" adjuvant formulation may also refer to a final adjuvant formulation comprising liposomes having a polydispersity index (PDI) of between about 0.05 and 0.5 or between about 0.05 and about 0.3, preferably about 0.3. Calculations for determining size and PDI parameters can be found in ISO standard documents 13321: 1996E and ISO 22412: 2008 (Worldwide MI Dynamic Light Scattering, Common Terms Defined. Malvern Instruments Limited; Malvern, UK: 2011. Pages 1-6. Inform White Paper). As used herein, a "homogeneous" adjuvant formulation shall also refer to a "monodisperse" adjuvant formulation.
[0231] As used herein, the term "heterogeneous" shall refer to a final adjuvant formulation comprising liposomes having a size range of about 30 nm to more than 10 microns, about 30 nm to 4 microns, about 30 nm to 1400 nm, preferably about 30 nm to 1000 nm as determined by methods known in the art, including but not limited to dynamic light scattering (DLS), transmission electron cryo-microscopy (e.g., cryo-TEM or cryo-EM), nanoparticle tracking analysis (NTA, e.g., ViewSizer). A "heterogeneous" adjuvant formulation may also refer to a final adjuvant formulation comprising liposomes having a polydispersity index (PDI) of >0.5. Calculations for determining size and PDI parameters can be found in ISO standard documents 13321: 1996E and ISO 22412: 2008 (Worldwide MI Dynamic Light Scattering, Common Terms Defined. Malvern Instruments Limited; Malvern, UK: 2011. Pages 1 to 6. Inform White Paper). As used herein, a "heterogeneous" adjuvant formulation shall also refer to a "polydisperse" adjuvant formulation.
[0232] As used herein, "liposome" refers to a closed bilayer membrane containing an entrapped water volume. Liposomes can also be unilamellar membrane vesicles with a single membrane bilayer or multilamellar membrane vesicles with multiple membrane bilayers, each membrane bilayer being separated from the next membrane bilayer by a water layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipids are toward the center of the bilayer, while the hydrophilic (polar) heads are toward the aqueous phase. When commonly used, liposomes are composed of a smectic mesophase, and can be composed of a phospholipid or non-phospholipid smectic mesophase. The smectic mesophase is most accurately described in Small, HANDBOOK OF LIPID RESEARCH, Vol. 4, Plenum, NY, 1986, pp. 49-50. According to Small, "When a given molecule is heated, rather than melting directly into an isotropic liquid, it passes through intermediate states called mesophases or liquid crystals, characterized by residual order in some directions but lack of order in others. In general, liquid crystals have molecules that are slightly longer than they are wide and have polar or aromatic moieties somewhere along the length of the molecule. The molecular shape and polar-polar or aromatic interactions cause the molecules to align in partially ordered arrays. These structures characteristically occur in molecules with polar groups at one end. Liquid crystals that have long-range order in the direction of the long axis of the molecule are called smectic, stratified, or lamellar liquid crystals. In the smectic state, the molecules can be in monolayers or bilayers, normal or tilted to the plane of the layers, and with frozen or melted aliphatic chains."
[0233] Lipid A is a group of complex, highly acylated and amidated diglucosamine diphosphate molecules, and is a lipid moiety common to all lipopolysaccharides (LPS; also known as endotoxins) from Gram-negative bacteria. LPS covers almost the entire outer surface of all Gram-negative bacteria, and lipid A anchors LPS to the outer lipid surface of bacteria. The O-polysaccharide portion of LPS in wild-type smooth bacteria is connected to a relatively conservative core oligosaccharide expressed in a rough mutant, and it is also connected to lipid A via a highly conservative 2-keto-3-deoxyoctanoic acid sugar, which is a unique chemical structure sometimes necessary for bacterial survival and is only found in LPS. See, for example, Alving et al., 2012, Expert Rev. Vaccines 11: 733-44. "Monophosphoryl lipid A" is a homologue of lipid A in which the glucosamine-1-phosphate group on the polar head group has been removed. There are also a large number of homologues of MPLA.
[0234] As used herein, the "molar percentage concentration of cholesterol" of a liposome composition refers to the ratio of cholesterol:total phospholipids (ie, phosphatidylcholine and phosphatidylglycerol) initially used to prepare the liposome composition.
[0235] As used herein, "physiologically acceptable carrier" refers to a carrier suitable for in vivo administration (e.g., oral, percutaneous or parenteral administration) or in vitro administration (i.e., cell culture). Exemplary physiologically acceptable carriers may be those physiologically acceptable components of the liposomes disclosed in U.S. Pat. Nos. 4,186,183 and 4,302,459.
[0236] As used herein, "preferably" and "preferably" should be interpreted for purposes of European claim construction only. These terms should be read or omitted from sentence and paragraph constructions in which the terms are presented for purposes of U.S. claim construction.
[0237] As used herein, the term "about" refers to ±5% of the stated value.
[0238] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that the singular forms "a", "an", and "the" as used herein include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an "antibody" includes a plurality of such antibodies, reference to a "dose" includes reference to one or more doses and their equivalents known to one of ordinary skill in the art, and so on.
[0239] 2. Saponin
[0240] For embodiments of the present invention, suitable saponins are Quil A, its derivatives or any purified fractions thereof (e.g., QS-7, QS-18, QS-21, or mixtures thereof). Quil A is a saponin preparation isolated from the South American tree Quillaja Saponaria Molina and was first found to have adjuvant activity. Dalsgaard et al., 1974, Archiv. fürdie gesanite Virusforschung, 44: 243-254. Purified fragments of Quil A, including, for example, QS-7 and QS-21 (also referred to as QA7 and QA21, respectively), have been isolated by HPLC (EP 0362 278). QS-21 is the 21st fraction purified from the sap of the Quillaja Saponaria tree. QS-21 has been shown to induce CD8+ cytotoxic T cells (CTL), Th1 cells, and a predominant IgG2a antibody response.
[0241] 3. Liposomes containing monophosphoryl lipid A (MPLA) (L(MPLA))
[0242] Liposomes are closed bilayer membranes containing an embedded water volume. Liposomes can also be unilamellar vesicles with a single membrane bilayer or multilamellar vesicles with multiple membrane bilayers, each membrane bilayer being separated from the next membrane bilayer by a water layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tail of the lipid is toward the center of the bilayer, while the hydrophilic (polar) head is toward the aqueous phase. Suitable hydrophilic polymers for surrounding liposomes include, but are not limited to, PEG, polyvinyl pyrrolidone, polyvinyl methyl ether, polymethyl oxazoline, polyethyl oxazoline, polyhydroxypropyl oxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropyl methacrylate, polyhydroxyethyl acrylate, hydroxymethyl cellulose, hydroxyethyl cellulose, polyethylene glycol, polyasparagine, and hydrophilic peptide sequences, such as described in U.S. Patent Nos. 6,316,024; 6,126,966; 6,056,973; and 6,043,094. Liposomes can be prepared in the absence of hydrophilic polymers. Thus, liposome preparations may or may not contain hydrophilic polymers.
[0243] Liposomes may comprise any lipid or lipid combination known in the art. For example, the lipids forming the vesicles may be naturally occurring lipids or synthetic lipids, including phospholipids (such as phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol and sphingomyelin), as disclosed in U.S. Pat. Nos. 6,056,973 and 5,874,104.
[0244] The vesicle-forming lipid may also be a glycolipid, a cerebroside, or a cationic lipid, such as 1,2-dioleoyloxy-3-(trimethylamino)propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1(2,3,-dioleoyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3[[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DCChol); or dimethyldioctadecylammonium (DDAB), as also disclosed in U.S. Pat. No. 6,056,973. Cholesterol can also be present in an appropriate range to impart liposome vesicle stability, as disclosed in U.S. Patents Nos. 5,916,588 and 5,874,104. Other liposome technologies are described in U.S. Patents Nos. 6,759,057; 6,406,713; 6,352,716; 6,316,024; 6,294,191; 6,126,966; 6,056,973; 6,043,094; 5,965,156; 5,916,588; 5,874,104; 5,215,680 and 4,684,479. These patents describe liposomes and lipid-coated microvesicles and methods for making them. Therefore, taking into account both the disclosures of the present invention and these other patents, those skilled in the art can produce liposomes for the purposes of embodiments of the present invention. For embodiments of the present invention, the liposome composition typically contains from about 1 mM to about 150 mM phospholipids.
[0245] Any of the above exemplary liposomes include monophosphoryl lipid A (MPLA), or may be combined with other liposomes and lipid A (MPLA). MPLA alone can be toxic to humans and animals. However, when MPLA is present in liposomes, no toxicity has been detected. See, e.g., Alving et al., 2012. MPLA acts as a potent adjuvant and is used to increase the immunogenicity of liposomes and peptides, proteins, or haptens associated with the liposomes.
[0246] For embodiments of the present invention, liposomes containing monophosphoryl lipid A (MPLA) (L(MPLA)) may be liposomes originally called Walter Reed liposomes, but currently called Army Liposome Formulation (ALF) (as a vaccine adjuvant). See, e.g., Alving et al., 2012. ALF adjuvant liposomes comprise: (1) a lipid bilayer comprising phospholipids, wherein the melting temperature of the hydrocarbon chains in water is ≥ 23°C, wherein the phospholipids are typically dimyristoylphosphatidylcholine (DMPC, e.g., 1,2-dimyristoyl-sn-glycero-3-phosphorylcholine) and dimyristoylphosphatidylglycerol (DMPG, e.g., 1,2-dimyristoyl-sn-glycero-3-phosphoryl-(1'-rac-glycerol)); (2) cholesterol (Chol) as a stabilizer; and (3) monophosphoryl lipid A (MPLA) as an immunostimulant. In human clinical trials, ALF-type liposome adjuvants have been shown to be safe and effective in candidate vaccines against malaria, HIV-1, and cancer. See, for example, Fries et al., 1992, Proc. Natl. Acad. Sci. USA, 89:358-62; Alving, 2002, Vaccine, 20:S56-64. The specific composition of ALF to which QS-21 is added to form ALFQ comprises cholesterol at a molar percentage concentration greater than about 50% (mol / mol), preferably about 55% to about 71% (mol / mol), or more preferably about 55% (mol / mol). In addition, in an embodiment of the present invention, the monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)) comprising a saponin (e.g., QS-21) may be a homogeneous LiNA-2 adjuvant formulation or a heterogeneous LiNA-2 adjuvant formulation as described herein.
[0247] For embodiments of the present invention, L(MPLA) may include a phosphatidylcholine (PC) selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC). L(MPLA) may also include a phosphatidylglycerol (PG) selected from the group consisting of dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), and distearoylphosphatidylglycerol (DSPG). The ratio (mol / mol) of PC to PG of the liposome may be about 0.5:1, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, or about 15:1. The liposomes may have an MPLA content of about 5 mg or less, about 4 mg or less, about 3 mg or less, about 2 mg or less, about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less, or about 0.01 mg or less (based on the total weight per ml of liposome suspension). Alternatively, the liposomes may have a molar ratio of MPLA:phospholipid of about 1:5.6 to about 1:880, preferably about 1:88 to about 1:220. Prior to the addition of saponin, the liposomes may comprise multilamellar vesicles (MLVs) or small unilamellar vesicles (SUVs). Small unilamellar vesicles may have a diameter of about 50 to about 100 nm, while multilamellar vesicles may have a diameter of about 1 to about 4 μm.
[0248] 4. Adjuvant formulations comprising liposomes containing MPLA (L(MPLA)) and saponin
[0249] GlaxoSmithKline previously introduced an adjuvant formulation called AS01 (also known as AS01B or AS01E). In AS01, the lipid bilayer contains neutral lipids that are "non-crystalline" at room temperature, such as dioleoylphosphatidylcholine, cholesterol, MPLA and QS-21. See U.S. Patent No. 10,039,823. During the manufacture of AS01, small unilamellar liposome vesicles (SUVs) are first produced, and then purified QS-21 is added to the SUVs. QS-21 gives unique properties because it binds to liposomal cholesterol, where QS-21 causes perforations (holes) or other permanent structural changes in the liposomes. See, for example, Paepenmuller et al., 2014, Int. J. Pharm., 475: 138-46. The reduction in the amount of free QS-21 may reduce the local injection pain usually caused by free QS-21. See, e.g., Waite et al., 2001, Vaccine, 19:3957-67; Mbawuike et al., 2007, Vaccine, 25:3263-69. AS01B formulations were generated for use in vaccines where induction of a still stronger T cell-mediated immune response is desired. et al., 2007, Expert. Rev. Vaccines, 6:723-39. AS01 preparations are being developed as adjuvants for various vaccines. See Garcon & Mechelen, 2011, Expert. Rev. Vaccines, 10:471-86. As described in U.S. Pat. No. 10,039,823, the AS01 preparation may contain cholesterol (sterol) at a molar percentage concentration of 1 to 50% (mol / mol), preferably 20 to 25% (mol / mol).
[0250] The present invention provides an adjuvant formulation produced by the method described herein, comprising a liposome composition containing monophosphoryl lipid A (MPLA) and at least one saponin, wherein the liposome composition comprises: i) a lipid bilayer comprising a phospholipid (e.g., dimyristoylphosphatidylcholine (DMPC) and / or dimyristoylphosphatidylglycerol (DMPG)), wherein the melting temperature of the hydrocarbon chain in water is ≥ 23°C, and ii) cholesterol, whose molar percentage concentration is greater than about 50% (mol / mol), or preferably about 55% to about 71% (mol / mol), or more preferably about 55% (mol / mol). At least these two characteristics are different from the characteristics of AS01 described above. The saponin can be selected from QS-7, QS-18, QS-21 or a mixture thereof, or the saponin can preferably be QS-21. The adjuvant formulation can contain about 1 mg or less, about 0.9 mg or less, about 0.8 mg or less, about 0.7 mg or less, about 0.6 mg or less, about 0.5 mg or less, about 0.4 mg or less, about 0.3 mg or less, about 0.2 mg or less, about 0.1 mg or less, about 0.09 mg or less, about 0.08 mg or less, about 0.07 mg or less, about 0.06 mg or less, about 0.05 mg or less, about 0.04 mg or less, about 0.03 mg or less, about 0.02 mg or less, about 0.01 mg or less of saponin in every ml of liposome suspension. In a preferred aspect, the adjuvant formulation comprises a saponin content of about 0.2 to 0.4 mg / ml.
[0251] In one aspect, the adjuvant formulation comprises a liposome composition comprising: i) a lipid bilayer comprising phospholipids and ii) cholesterol, wherein the molar ratio of cholesterol to phospholipid is greater than about 1.
[0252] In a preferred aspect, the liposome composition of the adjuvant formulation comprises PC and PG, wherein PC is dimyristoylphosphatidylcholine (DMPC) and PG is dimyristoylphosphatidylglycerol (DMPG), and has a molar ratio (mol / mol) of PC to PG of about 9:1.
[0253] In another aspect, the liposome composition of the adjuvant formulation may have a molar ratio of MPLA:phospholipid of about 1:5.6 to about 1:880, or about 1:88 to about 1:220. In a preferred embodiment, the liposome composition of the adjuvant formulation comprises PC and PG, wherein PC is dimyristoylphosphatidylcholine (DMPC) and PG is dimyristoylphosphatidylglycerol (DMPG), and has a molar ratio of MPLA:phospholipid of about 1:220, about 1:88 or about 1:5.6, preferably 1:88.
[0254] In another embodiment, the present invention provides an adjuvant formulation produced by the method described herein, wherein the adjuvant formulation comprises unilamellar liposomes having a liposomal bilayer, the liposomal bilayer being composed of: (a) at least one phosphatidylcholine (PC) and / or phosphatidylglycerol (PG) as phospholipids, the phospholipids being selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG) and distearoylphosphatidylglycerol (DSPG); (b) cholesterol; (c) monophosphoryl lipid A (MPLA); and (d) saponin; and wherein the molar ratio of cholesterol (b) to phospholipid (a) is greater than about 50:50; and wherein the unilamellar liposomes have a median diameter size in the micrometer range as detected by light scattering analysis. In one aspect, the saponin is QS-7, QS-18, QS-21 or a mixture thereof, preferably QS-21. In another aspect, the molar ratio of cholesterol (b) to phospholipid (a) is about 55:45 to about 71:29. In another aspect, the molar ratio of cholesterol (b) to phospholipid (a) is about 55:45. In another aspect, dimyristoylphosphatidylcholine (DMPC) is selected as the phospholipid, wherein dimyristoylphosphatidylglycerol (DMPG) is additionally selected as the phospholipid. In another aspect, both PC and PG are selected as phospholipids, and the ratio of PC to PG (mol / mol) is about 0.5:1, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1 or about 15:1. In another aspect, the present invention provides a liposome suspension comprising an adjuvant formulation as described herein and phosphate buffered saline (PBS) (pH 7.4), wherein the liposome suspension comprises (i) 1.272 mM to 50 mM phospholipid (a) and (ii) about 5 mg / ml or less MPLA (c). In another aspect, the molar ratio of MPLA (c) to phospholipid (a) is about 1:5.6 to about 1:880. In another aspect, the present invention provides a liposome suspension comprising the adjuvant formulation described herein and phosphate buffered saline (PBS) (pH 7.4), wherein the liposome suspension comprises (i) 1.272 mM to 50 mM phospholipid (a) and (ii) about 1 mg / ml or less saponin (d). In another aspect, the molar ratio of MPLA (c) to phospholipid (a) is about 1:88 to about 1:220.
[0255] Examples of adjuvant formulations comprising a liposome composition containing MPLA and at least one saponin (e.g., QS-21) prepared by the methods described herein include, but are not limited to, adjuvant formulations described in U.S. Pat. No. 10,434,167 (e.g., ALFQ) and two Liposomal Novel Adjuvant-2 (LiNA-2) adjuvant formulations described herein, namely, LiNA-2 homogeneous adjuvant formulation and LiNA-2 heterogeneous adjuvant formulation. In one aspect, the LiNA-2 adjuvant comprises a synthetic TLR4 agonist, monophosphoryl lipid A (MPLA), a triterpenoid glycoside saponin (QS-21), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (also known as dimyristoylphosphatidylcholine) (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (also known as dimyristoylphosphatidylglycerol) (DMPG), and cholesterol. In a preferred aspect, LiNA-2 comprises MPLA (e.g. ), QS-21, DMPC, DMPG and cholesterol. In another preferred aspect, LiNA-2 comprises MPLA (e.g. ), QS-21, DMPC, DMPG and cholesterol. In one aspect, the LiNA-2 adjuvant is designed to be reconstituted as a lyophilized powder formulation for administration. In another aspect, LiNA-2 is designed to be mixed with a liquid formulation for administration.
[0256] In another aspect, the LiNA-2 homogeneous or LiNA-2 heterogeneous adjuvant formulation can be a 1X concentration of LiNA-2 (1XLiNA-2) or a 2X concentration of LiNA-2 (2XLiNA-2) compared to the ALFQ concentration described herein. In one embodiment, the adjuvant formulation is ALFQ, which comprises (i) 7.0 mg / mL DMPC, (ii) 0.78 mg / ml DMPG, (iii) 5.4 mg / ml cholesterol, (iv) 0.2 mg / mL MPLA (3D-PHAD) and (v) 0.1 mg / ml QS-21. In another embodiment, the adjuvant formulation is 1XLiNA-2, wherein 1XLiNA-2 may be homogeneous or heterogeneous and comprises (i) 14±7 mg / mL DMPC, (ii) 1.6±0.8 mg / ml DMPG, (iii) 11±6 mg / ml cholesterol, (iv) 0.40±0.20 mg / mL MPLA (3D-PHAD) and (v) 0.20±0.10 mg / ml QS-21. In another embodiment, the adjuvant formulation is 2XLiNA-2, wherein 2XLiNA-2 may be homogeneous or heterogeneous and comprises (i) 28±14 mg / mL DMPC, (ii) 3.2±1.6 mg / ml DMPG, (iii) 22±11 mg / ml cholesterol, (iv) 0.80±0.40 mg / mL MPLA (3D-PHAD) and (v) 0.40±0.20 mg / ml QS-21.
[0257] 5. Use of adjuvant preparations comprising liposomes containing MPLA (L(MPLA)) and saponin
[0258] The adjuvant formulation of the present invention can be used to mix with an immunogen to obtain an immunogenic composition, such as a vaccine. The immunogenic composition may include a physiologically acceptable carrier, such as any of the carriers described in U.S. Pat. No. 5,888,519. The immunogenic composition may include naturally occurring or artificially produced proteins, recombinant proteins, glycoproteins, peptides, carbohydrates, nucleic acids, haptens, whole viruses, bacteria, protozoa or virus-like particles or conjugates thereof as immunogens. The immunogenic composition can be suitably used as an immunogenic composition against varicella or herpes zoster, human respiratory syncytial virus (RSV), cytomegalovirus infection (CMV), human metapneumovirus, human parainfluenza virus type 1 or 3, Lyme disease, Streptococcus pneumoniae, Clostridioides difficile, Escherichia coli or Klebsiella pneumoniae, influenza, HIV-1, hepatitis A, hepatitis B, human papillomavirus, meningococcal meningitis type A, meningococcal meningitis type B, meningococcal meningitis type C, tetanus, diphtheria, pertussis, polio, Haemophilus influenzae type B, dengue, hand, foot and mouth disease, typhoid, pneumococcus, Japanese encephalitis virus, The immunogenic composition can be suitably used in a method for treating or preventing a disease or infection caused by a pathogen associated with an infectious disease in a subject, preferably a human being, wherein the pathogen is selected from Acinetobacter baumannii, Anaplasma genus, Anaplasma phagocytophilum, Ancylostoma braziliense, Ancylostoma duodenale, Arcanobacterium haemolyticum, Ascaris lumbricoides, Aspergillus genus, Astroviridae, Babesia genus, Bacillus anthracis, and Bacillus cereus.anthracis, Bacillus cereus, Bartonella henselae, BK virus, Blastocystis hominis, Blastomyces dermatitidis, Bordetella pertussis, Borrelia burgdorferi, Borrelia genus, Borrelia spp, Brucella genus, Brugia malayi, Bunyaviridae family, Burkholderia cepacia and other Burkholderia species, Burkholderia mallei, Burkholderia pseudomallei, Caliciviridae family family), Campylobactergenus, Candida albicans, Candida spp, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, CJD prion, Clonorchissinensis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium perfringens, Clostridium spp, Clostridium tetani, Coccidioides spp, Coronavirus, Corynebacterium diphtheriae, Coxiella burnetii burnetii), Crimean-Congo hemorrhagic fever virus, Cryptococcusneoformans, Cryptosporidiumgenus), Cytomegalovirus (CMV), Dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4), Dientamoeba fragilis, Ebola virus (EBOV), Echinococcus genus, Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia genus, Entamoeba histolytica, Enterococcus genus, Enterovirus genus, Enterovirus (mainly Coxsackie A virus and enterovirus 71 (EV71)), Epidermophyton genus, spp), Epstein-Barr Virus (EBV), Escherichia coli O157:H7, Escherichia coli O111 and Escherichia coli O104:H4, Escherichia coli fimbriae antigen H, Fasciola hepatica and Fasciola gigantica, FFI prions, Filarioidea superfamily, Flaviviruses, Francisella tularensis, Fusobacterium genus, Geotrichumcandidum, Giardia intestinalis, Gnathostoma spp, GSS prions, Guanarito virus, Haemophilus ducreyi, Haemophilus influenzae, Helicobacter pylori pylori), Henipavirus (Hendra virus Nipah virus), Hepatitis A virus, Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis D virus, Hepatitis E virus, Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2), Histoplasma capsulatum, Human immunodeficiency virus (Humanimmunodeficiency virus (HIV), Hortaea werneckii, Human bocavirus (HBoV), Human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7), Human metapneumovirus (hMPV), Human papillomavirus (HPV), Human parainfluenza virus (HPIV), Japanese encephalitis virus, JC virus, Junin virus, Kingella kingae, Klebsiella granulomatis, Klebsiella pneumoniae, Kuru prion, Lassa virus, Legionella pneumophila, Leishmania genus, Leptospira genus, Listeria monocytogenes, Lymphocytic choriomeningitis virus (LCMV), choriomeningitis virus; LCMV), Machupo virus, Malassezia spp., Marburg virus, Measles virus, Metagonimus yokagawai, Microsporidiaphylum, Molluscum contagiosum virus (MCV), Mumps virus, Mycobacterium leprae and Mycobacterium lepromatosis, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Naegleria fowleri, Necator americanus), Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Nocardia spp., Onchocerca volvulusvolvulus), Orientia tsutsugamushi, Orthomyxoviridae family (influenza viruses), Paracoccidioides brasiliensis, Paragonimus spp., Paragonimus westermani, Parvovirus B19, Pasteurella genus, Plasmodium genus, Pneumocystis jirovecii, Poliovirus, Rabies virus, Respiratory syncytial virus (RSV), Rhinovirus, rhinoviruses, Rickettsia akari, Rickettsia genus, Rickettsia prowazekii prowazekii), Rickettsia rickettsii, Rickettsia typhi, Rift Valley fever virus, Rotavirus, Rubella virus, Sabia virus, Salmonella genus, Sarcoptes scabiei, SARS coronavirus, Schistosoma genus, Shigella genus, Sin Nombre virus, Hantavirus, Sporothrix schenckii, Staphylococcus genus, Staphylococcus genus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes pyogenes), Strongyloides stercoralis, Taenia genus, Taenia solium, Tick-borne encephalitis virusencephalitisvirus (TBEV), Toxocara canis or Toxocara cati, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp., Trichuris trichiura, Trypanosoma brucei, Trypanosoma cruzi, Ureaplasma urealyticum, Varicella-zostervirus (VZV), Variola major or minor, vCJD prions, Venezuelan equine encephalitis virus, Vibrio cholerae, cholerae, West Nile virus, Western equine encephalitis virus, Wuchereria bancrofti, Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis.
[0259] The present invention provides an immunogenic composition comprising an immunogen and an adjuvant formulation as described herein. Example
[0260] In order to better understand the present invention, the following examples are described. These examples are for illustrative purposes only and should not be construed as limiting the scope of the present invention in any way. The following examples illustrate some embodiments of the present invention.
[0261] In the following examples, dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidylglycerol (DMPG) and synthetic monophosphoryl lipid A (MPLA) (3D-PHAD TM) can be purchased from Avanti Polar Lipids (Alabaster, Ala., USA). Purified QS-21 can be purchased from Desert King International (San Diego, Calif., USA).
[0262] In addition, in the following examples, the cholesterol content can be analyzed by established methods to confirm the cholesterol concentration of the liposome composition and indirectly confirm the phospholipid concentration. See, for example, Zlatkis et al., 1953, J. Lab. Clin. Med., 41: 486-492. The cholesterol concentration of the liposome composition can be determined from a cholesterol standard curve.
[0263] Example 1: Preparation of homogeneous adjuvant formulation
[0264] Liposomes of various sizes are produced using a solvent injection method. Lipids (DMPG, DMPC, cholesterol and MPLA) are dissolved in an organic solvent (ethanol or isopropanol) by ultrasonic treatment, heating or a combination of the two, thereby forming liposomes (organic phase). The lipids (organic phase) in the organic solvent are heated to 65°C. The organic phase is pumped to a buffer (aqueous phase) maintained at room temperature (22°C to 25°C) or in a heated state (up to 60°C). The buffer (aqueous phase) is a 10mM phosphate solution containing 150mM NaCl at pH 6.2. The introduction of lipids (organic phase) can be as slow as 0.5mL / min to 400mL / min or lipids (organic phase) are quickly added to the buffer (aqueous phase).
[0265] The speed of adding lipid in buffer and the ratio of changing organic solvent and aqueous phase (buffer or water) by control make the size of formed liposome be in the scope of 40nm to 400nm.The ratio tested is in the scope of 1:4 to 1:16.Control liposome formation by stirring buffer and controlling the temperature of buffer at room temperature or under heating with 700rpm.Use high pressure extruder or microfluidizer to reduce the size of the liposome formed during this method.Control size by selecting the mesh size in the scope of 50nm to 120nm or using the homogenization pressure between 17000 and 24000PSI.After this process of reducing size, formed intermediate liposome is in the scope of 40 to 100nm, enables it to carry out aseptic filtration.
[0266] Table 1 provides data from multiple batches of intermediate liposomes formed.
[0267] Table 1
[0268]
[0269]
[0270] The organic solvent in the liposome can be removed before or after the size reduction. Using hollow fiber membrane or cassette membrane, ethanol is removed by tangential flow filtration. The concentration of the final product can be adjusted by controlling the ultrafiltration and diafiltration steps. The molecular weight cut-off (MWCO) of the membrane used for TFF is in the range of 100kDa to 500kDa. After TFF, the liposome is resuspended in a buffer and passed through a bioburden reduction filter (0.45 micron) and a sterile filter (0.22 micron).
[0271] The intermediate liposome containing MPLA is mixed (combined, mixed or altered) with a saponin (e.g., QS-21) in a sterile (sterile environment) manner to produce the final adjuvant drug product. The size of the final adjuvant has a range of 50 to 200 nm and a polydispersity of 0.05 to 0.3. During mixing, the mixing speed is set to 300 rpm. The mixing process ranges from 1 hour to 24 hours, wherein the mixing can be completed at room temperature or at 2° C. to 8° C.
[0272] Example of organic phase preparation:
[0273] Weigh the lipids (DMPC, DMPG and cholesterol) of twice the final concentration (1X), add to a glass vial and add to the required volume of ethanol to a sufficient amount (qs). 45ml 2X lipid solution is added to 360ml 10mM phosphate buffer (pH 6.2) containing 150mM NaCl at a ratio of 1:8. Heat a 50ml glass syringe at 50°C. Select the quality of lipids according to Table 2 for the preparation of 50ml lipid stock solution: 40mg MPLA (3D-PHAD) is added to the 2ml ethanol of each vial and ultrasonicated, while heating in a bath sonicator at 48°C for 30 minutes. Then, these MPLA (3D-PHAD) solutions are added to the beakers of other lipids weighed, and the total volume of the lipid stock solution is adjusted to 50ml.
[0274] Table 2: Lipid stock solutions (in 50 mL ethanol)
[0275]
[0276] Steps for batch preparation
[0277] 1. Pour 360 ml of PB into a 500 mL Pyrex medium storage bottle containing a white magnet.
[0278] 2. Set the syringe pump at (rate = 900 μl / min, syringe diameter = X mm (choose the appropriate diameter syringe based on the manual pump), volume = 45.00 ml).
[0279] 3. Wrap the syringe with a flat spiral heating pad and connect the pad to a temperature controller / heater. Set the heater temperature at 50°C.
[0280] 4. Using a needle, withdraw 50 mL of the ethanol lipid solution into a 50 ml wrapped glass syringe and remove any bubbles or gas inside. Remove the needle and cap the syringe immediately. Cut a 25 cm size 16 catheter and cap it from one side.
[0281] 5. Remove the cap from the syringe and immediately connect the open end of the catheter tip to the syringe.
[0282] 6. Place the media storage bottle containing PB on a hot plate while stirring inside with a magnet at -900 rpm at room temperature (22°C to 25°C).
[0283] 7. Open the other end of the catheter and place it in the media storage bottle.
[0284] 8. Fill the catheter with the lipid solution. Avoid any bubbles forming inside and cap the end of the catheter again after ensuring the lipids are ready to be added to the PB buffer.
[0285] 9. Open the catheter tip and place it in the media storage bottle. Start injection at 900 ul / min until 45.00 ml of lipid solution is added to the reaction bottle.
[0286] 10. Size measurement by DLS. 950 μl of milli Q water and 50 μl of sample. (DF=20).
[0287] The resulting sample was extruded using a 100 ml extruder. A 100 nm membrane was used for the first cycle, and 50 nm membranes were used for the second and third cycles, and each cycle was completed.
[0288] The pressure used for extrusion was between 400 psi and 500 psi in the 2nd and 3rd cycles, and between 600 psi and 700 psi in the first cycle of extrusion.
[0289] TFF was performed on the extruded samples using 100, 300 or 500 kDa MWCO mPES hollow fiber membranes. 275 ml of sample was concentrated to 50 ml and subjected to a 10 DV wash (using 500 ml of buffer) before the sample was concentrated to 35 mL.
[0290] The extruded liposomes are loaded onto a hollow fiber tangential flow system (500kDa mPES membrane). The total volume loaded is concentrated to a final volume to match the volume of the lipid solution. Complete the diafiltration volume wash (10 to 12 times) to remove all ethanol. Complete final size and concentration measurements before the intermediate liposome sterile filtration. The concentration of the intermediate liposome should be twice that of the final product. The intermediate liposome is stored at 2°C to 8°C and subsequently sterile filtered.
[0291] An appropriate amount of QS-21 (0.5 mg / mL to 2 mg / mL) was weighed and reconstituted using 10 mM phosphate buffer containing 150 mM sodium chloride at pH 6.2 to mix with the formed liposome intermediate and reach a final target concentration of 0.2 mg / mL or 0.4 mg / mL QS-21 in the adjuvant drug product. The solution of QS-21 was sterile filtered and mixed with the intermediate liposomes to produce the final adjuvant drug product.
[0292] Table 3 summarizes the dimensions and PDI of multiple batches of final adjuvant formulations produced according to the methods described in this example.
[0293] Table 3
[0294]
[0295]
[0296] Example 2: Preparation of homogeneous adjuvant formulations: Method for preparing intermediate liposomes of 40 to 150 nm using solvent injection without size reduction
[0297] A. Preparation of intermediate liposomes ranging from 40 to 150 nm
[0298] Weigh lipids (DMPG, DMPC, cholesterol, and MPLA) in a new glass bottle and add 100 ml of ethanol to prepare the lipid stock solution (organic phase) described in Table 4. Stir the lipid stock solution and heat the glass bottle in a water bath in a beaker at 45° C. After the lipids are dissolved, dilute the lipid stock solution 2.5 times with ethanol.
[0299] Table 4: Lipid stock solutions (in 100 mL ethanol)
[0300] Components MPLA-3D-PHAD DMPC DMPG cholesterol Actual weight added (mg) 80 2800.7 316.3 2164.1
[0301] The resulting liposomes were screened for size using NanoAssemblr with the conditions listed in Table 5. A flow ratio of 4:7 was selected for further use in the syringe injection method described in Section B below.
[0302] Table 5
[0303]
[0304] B. Syringe injection [Use liposomes with an intermediate size of 40 to 150 nm]
[0305] The lipid solution (organic phase) in ethanol described in Part A above is heated to 40°C to 65°C in a beaker placed on a heating plate, and loaded into a 60mL plastic / glass syringe (with 10mL of extra space). The syringe is wrapped in a heating pad so that the temperature is maintained between 45°C and 55°C. A total of 60mL lipid solution is loaded into an organic syringe. Water is heated to 45°C and loaded into a 120mL plastic syringe in a beaker placed on a heating plate. The syringe is maintained at 45°C using a heating pad. Aqueous phase and organic phase are connected by stainless steel Upchurch three-way assembly (Upchurch Stainless Steel Teeassembly) (Idex). The two syringes are connected to a pump, which is started simultaneously using software to produce 20ml liposomes according to the conditions in Table 6. The resulting liposomes are 40 to 140nm, and their PDI is 0.04 to 0.2.
[0306] The resulting liposomes were purified by TFF and concentrated to produce liposome intermediates with a size ranging from 40 to 91 nm and a PDI ranging from 0.05 to 0.1.
[0307] Table 6
[0308] Total volume: Volume of aqueous phase: Volume of organic phase: 150ml 95.45ml 54.55ml Total flow rate: Flow rate of water phase: Flow rate of organic phase: 12ml / min 7.636ml / min 4.363ml / min
[0309] C. Preparation of QS-21
[0310] 11 mg QS-21 was weighed into a 50 mL conical tube. 6.629 mL PBS buffer (10 mM phosphate, 150 mM NaCl, pH 6.2) was added to prepare a 1.5 mg / mL QS-21 solution. The QS-21 solution was shaken until the QS-21 was completely dissolved. The QS-21 stock solution was filtered using a 0.22 μM PES steri-flip filter. The stock solution was collected in a 50 mL conical tube and stored at 5 ° C and covered with aluminum foil.
[0311] D. Preparation of adjuvant products
[0312] 1 mL of the liposome intermediate from method B was mixed with 0.219 mL of QS-21 solution and 0.421 ml of PBS buffer. The combined solution was immediately covered with aluminum foil to avoid light exposure. It was then shaken at 350 rpm for 1 hour at room temperature and then stored at room temperature for 23 hours without stirring. The final formulation with a size of 102 nm and a PDI of 0.18 was stored at 2°C to 8°C as the final formulation. The concentration of the final adjuvant drug product contained a target range of 0.2 to 0.4 mg / mL QS-21.
[0313] The defined method was scaled up using a pump-based setup, where flow rates and mixing parameters were controlled as in the syringe setup described in Part B of this Example.
[0314] Example 3: Method for preparing heterogeneous adjuvant formulations
[0315] A. Method I: Method using solvent injection and microfluidizer
[0316] 1) Preparation of intermediates
[0317] Weigh lipids in a new glass bottle and add 100 ml of lipid stock solution in ethanol. The amount of lipid is the amount according to the table described below. A magnetic stir bar is placed in the bottle. Heat the glass bottle at 65°C in a water bath in a beaker. After the lipid is dissolved, dilute the sample 2.5 times with ethanol.
[0318] Table 7
[0319] Components MPLA-3D-PHAD DMPC DMPG cholesterol Ethanol (ml) Actual weight added (mg) 80 2800.7 316.3 2164.1 100
[0320] The lipid solution was heated to 65°C in a beaker placed on a hot plate and loaded into a 60 mL plastic syringe (with 10 mL extra space). Maintained at 65°C with the help of a heating pad wrapped around the syringe, which was secured with a zipper. The 60 mL lipid solution was loaded into an organic syringe. The WFI was heated to 60°C in a beaker placed on a hot plate and loaded into two 100 mL plastic syringes (with 10 mL extra space). Maintained at 60°C with the help of a heating pad wrapped around the syringe, which was secured with a zipper.
[0321] The organic phase settings used on the Adagio software / system are shown in Table 8.
[0322] Table 8
[0323]
[0324] The lipid solution (organic phase) in ethanol described in Part A above was heated to 65°C in a beaker placed on a heating plate and loaded into a 65mL plastic / glass syringe. The syringe was wrapped in a heating pad to maintain the temperature at about 65°C. A total of 60mL of lipid solution was loaded into an organic syringe. Water was heated to 60°C in a beaker placed on a heating plate and loaded into a 120mL plastic syringe. A heating pad was used to maintain the syringe at 60°C. The aqueous phase and the organic phase were connected by a steel upchurch tee assembly. The two syringes were connected to a pump, which was started simultaneously using software to produce 20ml liposomes according to the conditions in Table 8. The initial 5% of the operating sample was discarded. Ensure that the collected samples are not turbid and are collected in a glass container. The resulting liposomes are 40 to 70nm, and their PDI is 0.04 to 0.2.
[0325] In the concentration step, the 1200ml sample of the size of about 45nm and PDI about 0.04 to 0.1 merged from a few different batches is loaded gradually into the TFF system to obtain 60mL liposomes. During the diafiltration step, flow velocity is reduced to 400,300,200 and 100ml / min from 500ml / min at 10X point, then keeps stable from 10x to 20x with 100ml / min, feeds at 14psi, and carries out TMP at 7.5psi. The PBS buffer using about 10 times of dilution volumes of pH 6.2 is used for the buffer exchange starting with 100ml / min, flow velocity is increased to 200,300,400,500ml / min gradually, then keeps 500ml / min, feeds at 12psi, and carries out TMP at 8psi. With the flow velocity of about 200ml / min, only 60 to 64mL of retentate are obtained. The samples collected after TFF were filtered using a steriflip 50 mL filtration system with a 220 nm membrane to prepare liposomes with a size of approximately 55 nm and a PDI of approximately 0.13.
[0326] The liposome solution was further passed through the Y-shaped chamber of a microfluidizer about 10 times, followed by filtration to prepare an intermediate having a size of 58 nm and a PDI of 0.12.
[0327] 2) Preparation of QS-21
[0328] 11 mg of QS-21 was weighed into a 50 mL conical tube. 6.629 mL of PBS buffer (10 mM phosphate, 150 mM NaCl, pH 6.2) was added to prepare a 1.5 mg / mL QS-21 solution. The QS-21 solution was shaken until the QS-21 was completely dissolved. The QS-21 stock solution was filtered using a 0.22 μM PES steri-flip filter. The stock solution was collected in a 50 mL conical tube, stored at 5 ° C and covered with aluminum foil.
[0329] 3) Preparation of adjuvant products
[0330] 1 mL of the above intermediate was mixed with 0.219 mL of QS-21 solution and 0.421 ml of PBS buffer. The combined solution was immediately covered with aluminum foil to avoid light exposure. This was followed by shaking at 350 rpm for 1 hour at room temperature and then stored at room temperature for 48 hours without stirring. The final formulation with a size of 645 nm and a PDI of 0.62 was stored at 2° C. to 8° C. as the final formulation. The defined method was scaled up using a pump-based setup, wherein the flow rate and mixing parameters were controlled as described in the syringe setup.
[0331] B. Method II: Ethyl acetate injection method
[0332] 1) Preparation of intermediates
[0333] Weigh lipids and add them to a glass bottle with 155mL ethyl acetate and 5mL isopropanol (IPA) of the desired volume. Incubate lipids in a water bath at 55°C for 30 minutes to prepare a clear solution. The clarified lipid solution is loaded into a 50mL glass syringe wrapped with a heating pad so that the temperature is maintained at 55°C controlled by a temperature sensor. Using a syringe pump with a flow rate of 20mL / min, 4.5mL lipid solution is added to 36mL PBS buffer at pH 6.2. The preparation is purified and concentrated to 5 to 6mL by TFF, followed by 10DV to the PBS at pH 6.2. It is further concentrated to 1.7mL by centrifugation to prepare a liposome intermediate.
[0334] Table 9: The mass of lipids selected according to the table below is used to prepare 160 ml of lipid solution
[0335] name Actual amount (mg) DMPC 1127.2 DMPG 129.0 cholesterol 869.3 MPLA 34.1
[0336] Table 10: Size and distribution of different methods
[0337]
[0338] 2) Preparation of adjuvant products
[0339] 0.2 mL of 1.2 mg / mL QS-21 solution was added to 0.4 mL intermediate, followed by 2.25 mL PBS buffer at pH 6.2. The bottle was shaken on a shaker at 300 rpm for 1 hour at room temperature (RT). The solution was incubated for another 24 hours at RT. The final adjuvant formulation was stored at 5°C.
[0340] Table 11: Dimensions and PDI after each method
[0341] Methods Phase Size(nm) PDI Ethyl acetate injection 637 0.60 TFF 478 0.552 Concentration by centrifugation 462 0.695 Add QS-21 582 0.623 1 week at 5°C 542 0.649 2 weeks at 5°C 567 0.930
[0342] C. Method III: Method using freeze-dried lipids and rehydration with a microfluidizer
[0343] 1) Preparation of intermediates
[0344] The manufacture of the formulation involves weighing lipids MPLA (3D-PHAD), DMPC, DMPG and cholesterol, dissolving with preheated (55°C to 65°C) pure tert-butyl alcohol (TBA) and stirring at 300rpm for>30 minutes to completely dissolve. The final solution is loaded into a lyophilizer for use in the freeze / drying process. After the complete freezing step, the lyophilized lipids are then resuspended with 1 / 3 volume of 55°C to 60°C preheated buffer (PBS, pH 6.2) for rehydration. The concentration can be controlled by changing the buffer volume. Under stirring, rehydration is continued at 55°C to 60°C for at least 1 hour at 300rpm to form large liposomes ranging from nm to 10 microns. The LM10 microfluidizer is used and a pressure of about 18,640psi (set = 17,500psi) is applied in a 35°C to 45°C water bath to reduce the size of the liposomes, and the entire volume of the liposome solution is passed through about 5 to 12 times to produce small liposomes (50 to 100nm). The final liposome intermediate was filtered using a 0.22 μm PES sterile filter to produce a homogeneous liposome population with a particle size of about 40 to 70 nm and a low polydispersity (PDI of about 0.2). The final filtered liposomes as an intermediate can be stored at 5°C or further used to produce the final adjuvant product.
[0345] 2) Preparation of adjuvant products
[0346] To further manufacture the final formulation, the intermediate was equilibrated to room temperature and mixed with added PBS buffer and QS-21 solution (i.e., QS-21 at 1.5 mg / mL) in PBS buffer to prepare the final adjuvant formulation. Shaking at 300 rpm for 1 hour at room temperature followed by storage at room temperature (protected from light) for another 24 hours produced a final heterogeneous adjuvant product with a particle size of >300 nm and PDI>0.5. The final product was stored at 5°C and protected from light. The size and PDI in the three replicate preparations as shown in Table 12 were reproducible.
[0347] Table 12
[0348]
[0349] Example 4: Adjuvant formulation
[0350] The present invention provides methods for preparing MPLA-liposome adjuvant formulations containing saponin (e.g., QS-21) that can be scaled up. Exemplary MPLA-liposome adjuvant formulations containing saponin (e.g., QS-21) include, but are not limited to, MPLA-liposome formulations (e.g., ALFQ) described in U.S. Pat. No. 10,434,167 and two Liposomal Novel Adjuvant-2 (LiNA-2) adjuvant formulations described herein (i.e., LiNA-2 homogeneous adjuvant formulations and LiNA-2 heterogeneous adjuvant formulations), which may be 1XLiNA-2 concentration or 2XLiNA-2 concentration. The compositions of these adjuvant formulations are shown in Table 13 below:
[0351] Table 13: Adjuvant formulations
[0352]
[0353] *Described in Alving, CR et al., Expert Review of Vaccines 19:3 (2020) 279-292; and Hutter, JN et al., Vaccine 40 (2022) 5781-5790.
[0354] ** Formulation of both LiNA-2 homogeneous adjuvant formulation and LiNA-2 heterogeneous adjuvant formulation.
[0355] ***Formulation of both LiNA-2 homogeneous adjuvant formulation and LiNA-2 heterogeneous adjuvant formulation.
[0356] Example 5: Immunogenicity of Clostridium difficile vaccine antigens formulated with different LiNA-2 adjuvants
[0357] The relative immunogenicity of Clostridium difficile toxoid antigens formulated with aluminum hydroxide (Al(OH)3) and different LiNA-2 adjuvant formulations (homogeneous and heterogeneous) was compared in rats. Homogeneous and heterogeneous LiNA-2 adjuvants are described herein and in Table 14. The final rat LiNA-2 adjuvant dose was prepared by diluting 1X concentration of LiNA-2 at a 1:5 dilution using PBS buffer at pH 6.2.
[0358] Table 14. LiNA-2 adjuvant formulation
[0359]
[0360] The toxin neutralization assay (TNA) described below was used to measure the functional cytotoxic activity of sera at various time points after immunization.
[0361] Wistar Han rats (10 per group, 8 to 10 weeks old, Charles River Laboratories) were immunized intramuscularly (IM) according to the study design in Table 15. Group 1 received C. difficile vaccine antigen formulated with Al(OH)3. Groups 2 and 3 received C. difficile vaccine antigen formulated with homogeneous and heterogeneous LiNA-2 adjuvants, respectively.
[0362] Sera were collected at various time points and measured in TNA for the ability to neutralize the cytotoxic activity of the toxin. Figure 1 Neutralization titers of toxin B by sera from individual animals are shown in , indicating that toxoids formulated with homogeneous and heterogeneous LiNA-2 elicit similar immune responses that are capable of neutralizing the cytotoxicity of toxin B.
[0363] Table 15. Rat study design using LiNA-2 adjuvant formulation
[0364]
[0365] Toxin Neutralization Assay (TNA)
[0366] The immune response induced by administering the compositions of the present invention can be determined using a toxin neutralization assay (TNA), ELISA, or more preferably a cytotoxicity assay, such as the assays described in WIPO patent application WO / 2012 / 143902, U.S. Pat. No. 9,187,536, and WIPO patent application WO / 2014 / 060898, each of which is incorporated herein by reference in its entirety.
[0367] Toxin neutralization assay (TNA) can be used to quantify antibodies that neutralize Clostridium difficile toxins. In this assay, a fixed amount of Clostridium difficile toxin A or toxin B can be used to incubate a serial dilution of serum. Test cells (e.g., Vero cells) can then be added and the serum-toxin-cell mixture can be incubated under suitable conditions (e.g., 37°C for 6 days). The ability of serum to neutralize the cytotoxic effects of Clostridium difficile toxins can be determined by cell viability and is associated with cell viability. The assay utilizes the accumulation of acid metabolites in closed culture wells as an indication of normal cellular respiration. In cells exposed to toxins, metabolism and CO2 production are reduced; therefore, the pH rises (e.g., to 7.4 or higher), which can be indicated in the cell culture medium by a phenol red pH indicator. At this pH, the culture medium appears red. However, control cells or cells exposed to toxins that have been neutralized by antibodies metabolize and produce CO2 in normal amounts; therefore, the pH is maintained (e.g., at 7.0 or lower), at which the culture medium appears yellow. Therefore, Clostridium difficile toxin neutralizing antibodies are related to the ability of serum to neutralize the metabolic effects of Clostridium difficile toxins on cells, which can be demonstrated by its ability to maintain a certain pH (e.g., 7.0 or lower). The color change of the culture medium can be measured using an ELISA reader (e.g., at 562nm to 630nm) to further calculate the neutralizing antibody titer of the antitoxin when 50% of the cytotoxicity mediated by Clostridium difficile toxins is inhibited. In one aspect, the composition induces toxin neutralizing antibody titers, and when measured under the same conditions in a toxin neutralization assay, the toxin neutralizing antibody titer after an individual receives a dose of the composition is at least 1 times higher than the toxin neutralizing antibody titer before the individual receives the dose, for example, at least 1.01 times, 1.1 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 32 times or higher.
[0368] Briefly, in this example, 384-well microtiter plates were inoculated with IMR-90 cells, which serve as targets for toxin-mediated cytotoxicity. The ability of each test serum sample to neutralize toxin A or toxin B was analyzed separately. In a humidified incubator (37°C / 5% CO2), four serial dilutions of the test serum were mixed with a fixed concentration of toxin A (TcdA) or toxin B (TcdB) for 60 minutes to allow neutralization of the toxins to occur. All plates included reference standards and quality controls, which consisted of anti-toxin antibodies of known titer to monitor the performance of the assay. After 60 minutes of incubation, the toxin-antiserum mixture was applied to the IMR-90 cell monolayer and the plates were incubated for another 72 hours. Next, luciferase-based The viability of IMR-90 cell monolayers is tested with the ELISA kit, which provides a measure of ATP levels in metabolically active cells and is reported as relative luminescence units (RLU). High ATP levels indicate high cell viability and antibody-mediated neutralization of TcdA or TcdB. The results were analyzed using conventional statistical analysis systems. The neutralizing antibody concentration was determined by comparing the RLU values of the test samples with the calibration curves from the anti-toxin A or B reference standards. Functional antibody concentrations were expressed as arbitrary units / ml serum (or neutralizing units / ml serum). The lower limits of quantitation (LLOQ) of the TNA assay for TcdA and TcdB were 75.9 and 249.7 neutralizing units / ml serum, respectively.
Claims
1. A method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin and (c) a liposome composition, the liposome composition comprising (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG) and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), The method comprises the following steps: (i) dissolving the phospholipids, cholesterol and MPLA in an organic solvent to form an organic phase; (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes; (iii) stirring the liposomes in step (ii) to form intermediate liposomes; (iv) removing the organic phase of the intermediate liposomes in step (iii); (v) concentrating the intermediate liposomes in step (iv); and (vi) mixing the intermediate liposomes in step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5, Thereby the homogeneous adjuvant formulation is produced.
2. The method according to claim 1, wherein the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof.
3. The method according to claim 2, wherein the saponin is QS-21.
4. The method according to claim 1, wherein the phospholipid, cholesterol and MPLA in the step (i) are dissolved in the organic solvent by ultrasonic treatment, heating or a combination thereof.
5. The method according to claim 4, wherein the organic solvent is ethanol or isopropanol.
6. The process of claim 4, wherein the organic phase is heated to a temperature between 45°C and 65°C.
7. The method of claim 1, wherein the aqueous phase comprises water or a buffer.
8. The method of claim 7, wherein the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.
2.
9. The process of claim 7, wherein the aqueous phase is at a temperature between 20°C and 60°C.
10. The method according to claim 1, wherein the flow rate of step (ii) is 0.5 mL / min to 400 mL / min or rapid addition.
11. The method according to claim 1, wherein the intermediate liposomes in step (iii) are stirred at a rate of 700 rpm to 900 rpm.
12. The method according to claim 1, wherein the ratio of the organic phase to the aqueous phase of step (ii) is in the range of 1:4 to 1:
16.
13. The method according to claim 1, wherein the size of the intermediate liposomes in step (iv) is reduced by using a high pressure extruder or a microfluidizer.
14. The method of claim 13, wherein the size of the liposomes in step (iv) is reduced by using a membrane with a size range of 50 nm to 120 nm or a homogenization pressure between 17000 PSI and 24000 PSI, or a combination of both.
15. The method of claim 1, wherein the organic solvent is removed before the size reduction of step (iv) or after the size reduction of step (iv).
16. The method of claim 1, wherein the organic phase of the intermediate liposomes in step (iv) is removed by tangential flow filtration (TFF).
17. The method of claim 16, wherein the TFF is TFF diafiltration.
18. The method of claim 16, wherein the TFF comprises a membrane having a molecular weight cutoff (MWCO) ranging from 100 kDa to 500 kDa.
19. The method according to claim 1, wherein the concentration in step (v) is performed by ultrafiltration.
20. The method of claim 19, wherein the ultrafiltration comprises a bioburden reduction filter and a sterile filter.
21. The method of claim 1, wherein the mixing in step (vi) is performed at a mixing speed of 300 rpm.
22. The method of claim 1, wherein the mixing in step (vi) is in the range of 1 hour to 24 hours.
23. The method according to claim 1, wherein the mixing in step (vi) is performed at room temperature or at 2°C to 8°C.
24. The method of claim 1, wherein the final adjuvant formulation has a size range of about 30 nm to 400 nm.
25. The method of claim 1, wherein the final adjuvant formulation has a polydispersity of 0.05 to 0.
5.
26. The method of claim 1, wherein the injecting in step (ii) is performed by pump or syringe injection.
27. A method for producing a homogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, the liposome composition comprising (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), The method comprises the following steps: (i) dissolving the phospholipid, cholesterol and MPLA in an organic solvent or a mixture of organic solvents to form an organic phase; (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes; (iii) concentrating the intermediate liposomes in step (ii); (iv) removing the organic phase of the intermediate liposomes in step (iii); (v) filtering the intermediate liposomes in step (iv), and (vi) mixing the intermediate liposomes in step (v) with saponin to form a final adjuvant formulation having a size range of about 30 to 400 nm and a polydispersity of 0.05 to 0.5, Thereby the homogeneous adjuvant formulation is produced.
28. The method according to claim 27, wherein the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof.
29. The method of claim 28, wherein the saponin is QS-21.
30. The method according to claim 27, wherein the phospholipid, cholesterol and MPLA in the step (i) are dissolved in the organic solvent by sonication, heating, stirring or a combination thereof.
31. The method according to claim 30, wherein the organic solvent is ethanol or isopropanol or other organic solvents.
32. The process according to claim 30, wherein the organic phase is heated to a temperature between 45°C and 65°C, preferably between 50°C and 65°C or between 45°C and 55°C.
33. The method of claim 27, wherein the aqueous phase comprises water or a buffer.
34. The method of claim 33, wherein the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.
2.
35. The process of claim 33, wherein the aqueous phase is at a temperature between 20°C and 65°C.
36. The method of claim 27, wherein the flow rate in step (ii) is 12 mL / min.
37. The method of claim 27, wherein the intermediate liposomes in step (vi) are stirred at a rate of 100 rpm to 1000 rpm.
38. The method according to claim 27, wherein the ratio of organic phase to aqueous phase in step (ii) is in the range of 1:2 to 1:16, preferably 4:
7.
39. The method of claim 27, wherein the organic phase of the intermediate liposomes in step (iv) is removed by tangential flow filtration (TFF).
40. The method of claim 39, wherein the TFF is TFF diafiltration.
41. The method of claim 40, wherein the TFF comprises a membrane having a molecular weight cut-off (MWCO) in the range of 100 kDa to 500 kDa.
42. The method of claim 27, wherein the concentration in step (iii) is performed by ultrafiltration.
43. The method of claim 27, wherein the filtration in step (v) comprises a bioburden reduction filter and a sterile filter.
44. The method of claim 27, wherein the mixing in step (vi) is performed at a mixing speed of 350 rpm at room temperature for 1 hour.
45. The method of claim 27, wherein the final adjuvant formulation has a size range of about 50 nm to 200 nm.
46. The method of claim 27, wherein the final adjuvant formulation has a polydispersity of 0.05 to 0.
5.
47. The method of claim 27, wherein the injecting in step (ii) is performed by pump or syringe injection.
48. A method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, the liposome composition comprising (i) at least one phospholipid selected from at least one phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), The method comprises the following steps: (i) dissolving the phospholipids, cholesterol and MPLA in an organic solvent to form a lipid solution as an organic phase; (ii) injecting the organic phase in step (i) together with the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase simultaneously to form liposomes; (iii) concentrating the intermediate liposomes in step (ii); (iv) removing the organic phase of the intermediate liposomes in step (iii); (v) processing the intermediate liposomes in step (iv) by a microfluidizer at about 17,500 psi for 10 times; (vi) filtering the intermediate liposomes in step (v) using a 0.22 μm membrane; and (vii) mixing the intermediate liposomes in step (vi) with saponin, Thereby the heterogeneous adjuvant formulation is produced.
49. The method of claim 48, wherein the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof.
50. The method of claim 49, wherein the saponin is QS-21.
51. The method of claim 48, wherein in the step (i), the phospholipid, cholesterol and MPLA are dissolved in the organic solvent by sonication, heating, stirring or a combination thereof.
52. The method of claim 51, wherein the organic solvent is ethanol or isopropanol or a mixture thereof.
53. The method of claim 51, wherein the lipid preparation organic phase is heated to a temperature of 45°C to 65°C.
54. The method of claim 48, wherein the aqueous phase comprises water or a buffer.
55. The method of claim 54, wherein the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.
2.
56. The method of claim 54, wherein the aqueous phase is at a temperature between 45°C and 60°C.
57. The method according to claim 48, wherein the organic phase in step (ii) has a flow rate of 1.333 ml / min, and the aqueous phase has a flow rate of 10.667 ml / min (organic phase: aqueous phase = 1:8, using two syringes).
58. The method of claim 48, wherein the intermediate liposomes in step (iii) are stirred at a rate of 100 rpm to 900 rpm.
59. The method of claim 48, wherein the ratio of organic phase to aqueous phase in step (ii) is in the range of 1:4 to 1:
8.
60. The method of claim 48, wherein the organic phase of the intermediate liposomes in step (iii) and step (iv) is removed by tangential flow filtration (TFF).
61. The method of claim 60, wherein the size of the intermediate liposomes in step (iv) is manipulated by using a microfluidizer.
62. The method of claim 48, wherein the organic solvent is removed prior to the microfluidization in step (v).
63. The method of claim 60, wherein the TFF is TFF ultrafiltration and diafiltration.
64. The method of claim 60, wherein the TFF comprises a membrane having a molecular weight cutoff (MWCO) in the range of 100 kDa to 500 kDa.
65. The method of claim 48, wherein the concentration in step (iii) is performed by ultrafiltration.
66. The method of claim 48, wherein a buffer is added to the mixing in step (vi).
67. The method of claim 48, wherein the mixing in step (vii) is performed at room temperature at a mixing speed of 350 rpm for 1 hour to 48 hours or stirring for 1 hour.
68. The method of claim 67, wherein after the mixing in step (vii), the intermediate liposomes are stored at room temperature without stirring for up to 48 hours.
69. The method of claim 48, wherein the final adjuvant formulation has a size of about 300 nm to 1000 nm.
70. The method of claim 48, wherein the final adjuvant formulation has a polydispersity of 0.4 to 1.
71. The method of claim 48, wherein the injecting in step (ii) is performed by Nanoassembly or pump or syringe injection.
72. A method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, the liposome composition comprising (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), The method comprises the following steps: (i) dissolving the phospholipids, cholesterol and MPLA in an organic solvent to form a lipid preparation as an organic phase; (ii) injecting the organic phase in step (i) into the aqueous phase at a specific flow rate and a specific ratio of the organic phase to the aqueous phase to form liposomes; (iii) stirring the liposomes in step (ii) to form intermediate liposomes; (iv) concentrating the intermediate liposomes in step (iii); (v) removing the organic phase of the intermediate liposomes in step (iv); and (vi) mixing the intermediate liposomes in step (v) with saponin, Thereby the heterogeneous adjuvant formulation is produced.
73. The method of claim 72, wherein the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof.
74. The method of claim 73, wherein the saponin is QS-21.
75. The method of claim 72, wherein in the step (i), the phospholipid, cholesterol and MPLA are dissolved in the organic solvent by sonication, heating, stirring or a combination thereof.
76. The method of claim 75, wherein the organic solvent comprises ethyl acetate and isopropanol.
77. The method of claim 75, wherein the lipid preparation organic phase is heated to a temperature of 50°C to 65°C.
78. The method of claim 72, wherein the aqueous phase comprises water or a buffer.
79. The method of claim 78, wherein the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.
2.
80. The method of claim 78, wherein the aqueous phase is at a temperature of 20°C to 25°C.
81. The method of claim 72, wherein the flow rate in step (ii) is 20 mL / min.
82. The method of claim 72, wherein the intermediate liposomes in step (iii) are stirred at a rate of 100 rpm to 900 rpm.
83. The method of claim 72, wherein the ratio of organic phase to aqueous phase in step (ii) is in the range of 1:4 to 1:
8.
84. The method of claim 72, wherein the organic solvent is removed prior to the mixing in step (vi).
85. The method of claim 72, wherein the organic phase of the intermediate liposomes in step (iv) and step (v) is removed by tangential flow filtration (TFF).
86. The method of claim 85, wherein the TFF is TFF ultrafiltration and diafiltration.
87. The method of claim 85, wherein the TFF comprises a membrane having a molecular weight cutoff (MWCO) in the range of 100 kDa to 500 kDa.
88. The method of claim 72, wherein the concentration in step (vi) is performed by ultrafiltration.
89. The method of claim 72, wherein a buffer is added to the mixing in step (vi).
90. The method of claim 72, wherein the mixing in step (vi) is performed at a mixing speed of 300 rpm at room temperature for 1 hour.
91. The method of claim 90, wherein after the mixing in step (vii), the intermediate liposomes are stored at room temperature for 24 hours without stirring.
92. The method of claim 72, wherein the final adjuvant formulation has a size range of 300 nm to 1000 nm.
93. The method of claim 72, wherein the final adjuvant formulation has a polydispersity of 0.4 to 1.
0.
94. The method of claim 72, wherein the injecting in step (ii) is performed by pipette, pump or syringe injection.
95. A method for producing a heterogeneous adjuvant formulation comprising a liposome bilayer, the liposome bilayer comprising (a) monophosphoryl lipid A (MPLA), (b) saponin, and (c) a liposome composition, the liposome composition comprising (i) at least one phospholipid selected from phosphatidylcholine (PC) and / or phosphatidylglycerol (PG), wherein the phospholipid is selected from the group consisting of dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), and combinations thereof, and (ii) cholesterol, wherein the molar percentage concentration of cholesterol in the liposome composition is greater than 50% (mol / mol), The method comprises the following steps: (i) preparing a lyophilized organic phase comprising the phospholipid, cholesterol and MPLA; (ii) rehydrating the lyophilized organic phase in step (i) with an aqueous phase to form intermediate liposomes; (iii) reducing the size of the intermediate liposomes in step (ii) using a microfluidizer; (iv) mixing the intermediate liposomes in step (iii) with saponin, Thereby the heterogeneous adjuvant formulation is produced.
96. The method of claim 95, wherein the saponin is selected from the group consisting of QS-7, QS-18, QS-21 or a mixture thereof.
97. The method of claim 96, wherein the saponin is QS-21.
98. The method of claim 95, wherein in the step (i), the phospholipids, cholesterol and MPLA are dissolved in the organic solvent by sonication, heating, stirring or a combination thereof.
99. The method of claim 98, wherein the organic solvent comprises tert-butyl alcohol (TBA) or a mixture thereof.
100. The method of claim 99, wherein the lipid organic phase is heated to a temperature of 25°C to 65°C.
101. The method of claim 100, wherein the organic phase solution is lyophilized.
102. The method of claim 95, wherein the aqueous phase comprises water or a buffer.
103. The method of claim 102, wherein the buffer comprises 10 mM phosphate containing 150 mM NaCl at pH 6.
2.
104. The method of claim 102, wherein the aqueous phase is at a temperature of 20°C to 70°C.
105. The method of claim 95, wherein the intermediate liposomes in step (ii) are stirred at a rate of 100 rpm to 1000 rpm.
106. The method of claim 95, wherein the intermediate liposomes in step (iii) are reduced in size using a microfluidizer and a pressure of 18640 PSI.
107. The method of claim 95, wherein the organic solvent is removed prior to rehydration in step (ii).
108. The method of claim 95, wherein the organic solvent is removed by lyophilization.
109. The method of claim 95, wherein a buffer is added to the mixing in step (iv).
110. The method of claim 95, wherein the mixing in step (iv) is performed at a mixing speed of 300 rpm for 1 hour at room temperature or stirring for 1 hour.
111. The method of claim 110, wherein after the mixing in step (iv), the intermediate liposomes are stored at room temperature for 24 hours without stirring.
112. The method of claim 95, wherein the final adjuvant formulation has a size >300 nm.
113. The method of claim 95, wherein the final adjuvant formulation has a polydispersity > 0.
4.
114. An adjuvant formulation produced by the method according to any one of claims 1 to 113.
